Nippon Shinyaku Co., Ltd.

4516.T

4516.TNippon Shinyaku Co., Ltd. JP flag

Tokyo Stock Exchange

3,047.00

JPY

+34.00

(+1.13%)

483.11EPS

6.31P/E

205.30BMarket Cap

Aug 07Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

JP3717600005

Return %

Stock

S&P500

-12.67

10.59

-62.98

63.55

-60.94

94.73

Use logarithmic scale

	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y	TTM
Revenue per Share	1,036.39	1,134.34	1,186.72	1,249.91	1,466.42	1,506.17	1,703.18	1,731.73	1,809.26	2,041.25	2,140.62	2,201.2	2,379.02	1,112.69
Basic EPS, GAAP	68.86	85.24	87.26	94.1	174.42	192.31	242.03	250.41	290.11	370.97	338.7	383.82	483.4	143.65
Free Cash Flow per Basic Share	35.39	70.45	71.92	107.03	216.2	37.74	205.66	162.13	302.87	183.7	214.43	98.59	19.79	38.93
Dividend per Share	20	22	24	27	31.98	55.94	54.9	83.9	91.99	100.95	115.94	118.94	123.95	61.97
Book Value per Share	1,215.28	1,279.06	1,339.83	1,407.59	1,559.8	1,696.27	1,883.35	2,038.29	2,256.32	2,531.1	2,755.78	3,020.46	3,382.44	3,201.62
Tangible Book Value per Share	1,316.74	1,373.12	1,494.67	1,517.86	1,689.71	1,858.84	2,001.02	2,057.24	2,280.74	2,477.01	2,654.35	2,901.38	2,954.98	3,061.16
Basic Weighted Avg Shares	67	67	67	67	67	67	67	67	67	67	67	67	67	67
Sales/Revenue/Turnover	69,941	76,517	79,991	84,209	98,781	101,448	114,716	116,637	121,859	137,484	144,175	148,255	160,232	74,940
Operating Margin (%)	9.87	10.51	10.71	10.16	15.47	16.84	18	18.58	22.32	23.96	20.84	22.46	22.12	16.57
Depreciation Expense	2,759	2,704	2,665	2,452	2,648	2,773	3,418	3,468	4,400	4,588	5,041	5,023	6,015	2,561
Net Income, GAAP	4,647	5,750	5,882	6,340	11,749	12,953	16,302	16,866	19,540	24,986	22,812	25,851	32,558	9,675
Effective Tax Rate (%)	36.41	33	34.04	29.1	23.98	25.68	24.22	24.74	29.15	24.93	25.15	23.09	9.89	22.4
Profit Margin (%)	6.64	7.51	7.35	7.53	11.89	12.77	14.21	14.46	16.03	18.17	15.82	17.44	20.32	12.91
Working Capital	55,255	59,426	62,652	64,832	71,786	72,722	85,314	94,303	104,857	117,695	122,690	126,949	119,424	132,114
LT Debt	- -	- -	- -	- -	- -	- -	- -	866	1,383	1,219	1,148	1,152	1,374	1,234
Total Equity	89,527	93,185	101,206	102,762	114,316	125,686	135,189	146,860	163,448	180,884	195,931	220,534	247,339	235,250
Return on Invested Capital (%)	4.94	5.77	5.67	5.79	10.39	10.3	11.68	11.21	11.9	13.75	11.49	11.86	13.26	4.21
Return on Capital (%)	5.76	6.81	6.64	6.83	11.72	11.78	13.48	12.63	13.31	15.26	12.65	13.21	14.94	4.72
Return on Common Equity (%)	5.78	6.83	6.66	6.85	11.75	11.81	13.52	12.77	13.51	15.5	12.81	13.29	15.1	4.68

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	7.31%	6.62%	8.08%
Net Income, GAAP	20.7%	14.86%	25.94%
Free Cash Flow	42.22%	-13.95%	-79.92%
Total Cash Common Dividend	19.77%	8.21%	4.21%
Total Equity	9.39%	11%	12.15%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Toru Nakai
Full Time Employees: 2,213
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: 14, Nishinosho-Monguchi-cho Kyoto Japan 601-8550
IPO Date: Jan 1, 2001
Website: nippon-shinyaku.co.jp
Similar Companies: Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
Towa Pharmaceutical Co., Ltd. (TWAPF)
Jiangsu Kanion Pharmaceutical Co.,Ltd. (600557.SS)
Jeil Pharmaceutical Co.,Ltd (271980.KS)
Brooks Laboratories Limited (BROOKS.BO)
Orexo AB (publ) (ORXOY)
Business: Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y	TTM
Revenue per Share	1,036.39	1,134.34	1,186.72	1,249.91	1,466.42	1,506.17	1,703.18	1,731.73	1,809.26	2,041.25	2,140.62	2,201.2	2,379.02	1,112.69
Basic EPS, GAAP	68.86	85.24	87.26	94.1	174.42	192.31	242.03	250.41	290.11	370.97	338.7	383.82	483.4	143.65
Free Cash Flow per Basic Share	35.39	70.45	71.92	107.03	216.2	37.74	205.66	162.13	302.87	183.7	214.43	98.59	19.79	38.93
Dividend per Share	20	22	24	27	31.98	55.94	54.9	83.9	91.99	100.95	115.94	118.94	123.95	61.97
Book Value per Share	1,215.28	1,279.06	1,339.83	1,407.59	1,559.8	1,696.27	1,883.35	2,038.29	2,256.32	2,531.1	2,755.78	3,020.46	3,382.44	3,201.62
Tangible Book Value per Share	1,316.74	1,373.12	1,494.67	1,517.86	1,689.71	1,858.84	2,001.02	2,057.24	2,280.74	2,477.01	2,654.35	2,901.38	2,954.98	3,061.16
Basic Weighted Avg Shares	67	67	67	67	67	67	67	67	67	67	67	67	67	67
Sales/Revenue/Turnover	69,941	76,517	79,991	84,209	98,781	101,448	114,716	116,637	121,859	137,484	144,175	148,255	160,232	74,940
Operating Margin (%)	9.87	10.51	10.71	10.16	15.47	16.84	18	18.58	22.32	23.96	20.84	22.46	22.12	16.57
Depreciation Expense	2,759	2,704	2,665	2,452	2,648	2,773	3,418	3,468	4,400	4,588	5,041	5,023	6,015	2,561
Net Income, GAAP	4,647	5,750	5,882	6,340	11,749	12,953	16,302	16,866	19,540	24,986	22,812	25,851	32,558	9,675
Effective Tax Rate (%)	36.41	33	34.04	29.1	23.98	25.68	24.22	24.74	29.15	24.93	25.15	23.09	9.89	22.4
Profit Margin (%)	6.64	7.51	7.35	7.53	11.89	12.77	14.21	14.46	16.03	18.17	15.82	17.44	20.32	12.91
Working Capital	55,255	59,426	62,652	64,832	71,786	72,722	85,314	94,303	104,857	117,695	122,690	126,949	119,424	132,114
LT Debt	- -	- -	- -	- -	- -	- -	- -	866	1,383	1,219	1,148	1,152	1,374	1,234
Total Equity	89,527	93,185	101,206	102,762	114,316	125,686	135,189	146,860	163,448	180,884	195,931	220,534	247,339	235,250
Return on Invested Capital (%)	4.94	5.77	5.67	5.79	10.39	10.3	11.68	11.21	11.9	13.75	11.49	11.86	13.26	4.21
Return on Capital (%)	5.76	6.81	6.64	6.83	11.72	11.78	13.48	12.63	13.31	15.26	12.65	13.21	14.94	4.72
Return on Common Equity (%)	5.78	6.83	6.66	6.85	11.75	11.81	13.52	12.77	13.51	15.5	12.81	13.29	15.1	4.68

	Mar'24	Jun'25	Sep'25
ST Debt	1,720	- -	1,317
LT Borrowings	- -	- -	- -
LT Finance Leases	1,152	- -	1,234
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	67	- -	67
Market Capitalization	296,283	215,747	250,948

	Mar'24	Jun'25	Sep'25
Total Current Assets	164,285	- -	159,826
Accounts Receivable, Net	47,237	- -	43,071
Cash, Cash Equivalents & STI	68,703	- -	66,020
Inventories	39,111	- -	42,805
Total Current Liabilities	37,336	- -	27,712
Payables & Accruals	- -	- -	- -
ST Debt	1,720	- -	1,317
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	35,619	35,517	38,783	34,256	144,175
2024	37,012	36,301	39,413	35,527	148,255
2025	- -	- -	- -	- -	160,232

Year	Q1	Q2	Q3	Q4	FY
2023	55.72	3.24	53.87	- -	115.94
2024	53.82	3.15	58.62	- -	118.94
2025	- -	- -	- -	- -	123.95

Year	Q1	Q2	Q3	Q4	FY
2023	122.47	103.51	110.64	- -	338.7
2024	129.9	110.26	116.2	- -	383.82
2025	- -	- -	- -	- -	483.4

Nippon Shinyaku Co., Ltd.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year